Objective To detect clopidogrel effect with light transmission aggregometry (LTA)and flow cytometry (FC). Methods ①Venous blood samples were taken from 71 inpatient with acute corotary syndrome (ACS)in PLA General Hos-pital,including unstable anqina,ST segment elevation myocardial infarction and non ST segment elevation myocardial infarc-tion (46 males,25 females)by random number table from June 2011 to March 2012,whose average age was 69(57~92).②All of them were served 160 mg aspirin and 300 mg clopidogrel after they were in hospital in the beginning,and then served with 75 mg/d clopidogrel for 6 months.On some day,firstly,they were required withdrawing drug for 10 days,and then ve-nous blood samples were separately taken from them before their served-clopidogrel again and their severd-clopidogrel 2 hours later.③The samples were assayed with LTA and FC simultaneously and the platelet aggregation rates before served-clopidogrel (ADPLTA-before serving ),platelet aggregation rates after served-clopidogrel (ADPLTA-after serving ),inhibition rates (ADPLTA-INDU ),PAC-1 activity percentage before served-clopidogrel (PAC-1 before serving ),PAC-1 activity percentage after served-clopidogrel (PAC-1 after serving ),inhibition rates (PAC-1 INHI ),CD62p activity percentage before served-clopidogrel (CD62pbefore serving ),CD62pactivity percentage after served-clopidogrel (CD62pafter serving ),inhibition rates (CD62pINHI )weregotten.All volunteers were signed informed consents and the experiment was approved by the hospital ethics committee.Re-sults ①The paired samples t-test was (t=-2.082,P =0.041)between ADPLTA-before serving (0%~97%)and ADPLTA-after serving (12%~97%),the paired samples t-test was (t = 3.663,P < 0.01)between PAC-1 before serving (15.1% ~ 78.9%)and PAC-1 after serving (14.5% ~ 78.3%);the paired samples t-test was (t = 2.082 and P = 0.041)between CD62pbefore serving (1.5% ~80.8%)and CD62pafter serving (1.4%~41.4%).②The pearson coeffcient correlation results were:ADPLTA-INDU (0%~28.2%) and PAC-1 INHI (0.6%~ 9.1%)(r = 0.297,P = 0.012);ADPLTA-INDU (0% ~ 28.2%)and CD62pINHI (0.1% ~ 48.5%)(r =0.220,P =0.065);PAC-1 INHI (0.6%~9.1%)and CD62pINHI (0.1%~48.5%)(r=0.736,P <0.001).Conclusion Because the correlation was bad between the inhibition rates of clopidogrel detected by FC and them by LTA,FC didn’t apply to clin-ical routine examination of the platelet aggregation.But it could be used to scientific researchs and auxiliary confirmation of routine examination results.%目的：采用二磷酸腺苷（adenosine phosphate，ADP）诱导光电比浊法血小板聚集分析仪（light transmittance aggre-gometry，LTA）试验与流式细胞仪（flow cytometry，FC）血小板膜糖蛋白分子 PAC-1（Fg，Ca2＋，GPⅡb／Ⅲa 形成复合物的受体）、CD62p（P 选择素）活性百分数实验检测氯吡格雷的抗血小板聚集效果。方法①用随机数字表法收集解放军总医院住院的2011年6月～2012年3月急性冠状动脉综合征（acute coronary syndrome，ACS）术后患者71例（包括不稳定型心绞痛、ST 段抬高型心肌梗死、非 ST 段抬高型心肌梗死患者）。男性46例，女性25例，平均年龄69岁（57～92岁）。②患者入院时均先顿服阿司匹林160 mg 和氯吡格雷300 mg，之后用氯吡格雷75 mg／d 的维持量治疗6个月后，在某次停药10天后，于服药前、服药后2 h 采集其前臂静脉血。③同时进行 LTA 和 FC 检测，分别得到 ADP 诱导的患者服药前、后LTA 检测的血小板聚集率及药物抑制率（分别用 ADPLTA服药前、ADPLTA服药后、ADPLTA-INDU表示）；FC 检测的 PAC-1活性百分数及药物抑制率（分别用 PAC-1服药前、PAC-1服药后、PAC-1 INHI 表示），CD62p 活性百分数及药物抑制率（分别用 CD62p服药前、CD62p服药后、CD62pINHI表示）。所有参与实验者均签署了知情同意，该研究获得医院伦理委员会批准。结果①71例观察对象均进入结果分析。②ADPLTA服药前值分布在0％～97％（73.5±13.7）％，ADPLTA 服药后值分布在12％～97％（63.6±16.2）％，两者进行成组数据配对样本 t 检验（t ＝－2.082，P ＝0.041）；PAC-1服药前值分布在15.1％～78.9％（49.8±17.8）％，PAC-1服药后值分布在14.5％～78.3％（47.9±17.1）％，两者进行成组数据配对样本 t 检验（t＝3.663，P ＜0.01）；CD62p服药前值分布在1.5％～80.8％（10.9±9.8）％，CD62p服药后值分布在1.4％～41.4％（9.3±6.7）％，两者进行成组数据配对样本 t 检验（t ＝2.082，P ＝0.041）。③ ADPLTA-INDU 值分布在0％～28.2％（13.8±13.9）％，PAC-1 INHI 值分布在0.6％～9.1％（3.7±3.8）％，CD62pINHI值分布在0.1％～48.5％（15.0±32.3）％，三者两两之间采用积矩相关系数（Pear-son 相关系数）判别：ADPLTA-INDU 与 PAC-1 INHI （r＝0.297，P ＝0.012），ADPLTA-INDU与 CD62pINHI （r＝0.220，P ＝0.065），PAC-1 INHI与 CD62pINHI （r＝0.736，P ＜0.001）。结论FC 检测的氯吡格雷药物抑制率与 LTA 的相应值相关性不好，FC 并不适用于血小板聚集功能的临床常规检测，但可作为科学研究及常规结果的辅助性确认方法。
展开▼
